0
Summaries for Patients |

Effects of Drug Treatment for Obesity in Adolescence FREE

[+] Article and Author Information

The summary below is from the full report titled “Effects of Sibutramine Treatment in Obese Adolescents. A Randomized Trial.” It is in the 18 July 2006 issue of Annals of Internal Medicine (volume 145, pages 81-90). The authors are R.I. Berkowitz, K. Fujioka, S.R. Daniels, A.G. Hoppin, S. Owen, A.C. Perry, M.S. Sothern, C.L. Renz, M.A. Pirner, J.K. Walch, O. Jasinsky, A.C. Hewkin, and V.A. Blakesley, for the Sibutramine Adolescent Study Group.


Ann Intern Med. 2006;145(2):I-16. doi:10.7326/0003-4819-145-2-200607180-00004
Text Size: A A A

What is the problem and what is known about it so far?

Being obese during adolescence is an increasing problem in the United States; 15% of adolescents are obese. Obesity is a serious problem. It increases the likelihood of having diabetes or heart disease later in life and of dying while still in middle age. Adolescents who are obese are more likely to be depressed or to feel unpopular with schoolmates. Adolescents have trouble losing weight and keeping it off. In a clinical trial in obese adolescents, sibutramine caused weight loss, but the study lasted only 6 months.

Why did the researchers do this particular study?

To see whether sibutramine reduces weight more than placebo in obese adolescents who are receiving counseling to help them exercise more and reduce the amount of food that they eat.

Who was studied?

498 obese adolescent boys and girls 12 to 16 years of age.

How was the study done?

The researchers randomly assigned 368 participants to receive sibutramine (10 mg) and 130 participants to receive placebo (sugar pill) once a day for 1 year. All participants regularly received counseling about how to eat less food, increase physical activity, reduce stress, and keep track of how much they ate. The researchers then measured weight, blood pressure, and pulse rate every month.

What did the researchers find?

The average weight of participants before the study was 215 pounds. Adolescents who took sibutramine usually lost weight (about 14 pounds), while those who took placebo usually gained weight (about 4 pounds). At 1 year, the average difference in weight between groups was 18.5 pounds. Participants who took sibutramine on average lost weight rapidly during the first 8 months and then maintained weight until 1 year. They also gained height and matured sexually at the same rate as those who took placebo. The main drug side effect was rapid heart rate, which occurred in 12.5% of participants receiving sibutramine and 6.2% of participants who took placebo. The number of participants who stopped taking their study pills because of side effects was similar in both groups.

What were the limitations of the study?

The study lasted only 1 year, which is not long enough to measure the long-term benefits or harms of sibutramine in adolescents. It did not measure changes in weight after stopping sibutramine treatment. About one quarter of the participants did not complete the study.

What are the implications of the study?

In obese adolescents who were getting counseling to lose weight, taking sibutramine reduced weight and did not affect physical maturation.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)